SKRUMBLE-NETWORK
2.8.2018 13:02:06 CEST | Business Wire | Press release
Skrumble Network (SKM), a communication-centric public blockchain that simplifies the way people contact and contract, today announced the global Beta release of its first dApp – Ally – on iOS and Android. Currently centralized in Beta, and soon to be decentralized in September 2018, Ally is the first of its kind, multi-purpose mobile media and communication application that enables users around the world to communicate freely, anonymously, and securely. Unlike Facebook, Telegram and WeChat, the new dApp is powered by the Skrumble Network public chain, and therefore uses community-owned storage with no centralized servers. This ensures that no external entities have the power to censor, block or manipulate any data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005093/en/
“We’re excited to mark this milestone in our project, where the shared vision of uniting the global community is becoming a reality,” says Eric Lifson, Co-Founder of Skrumble Network. “There is a pressing demand for a communication platform that places user privacy, data security, and freedom all first, and we are combatting this issue by building Ally to create an environment where people can feel safe.”
Some key features of Ally (Beta) are:
- Disappearing messages with set timers
- Private, public and broadcast chat functionalities
- Video chat with up to 50 members
- Live media streaming
- In-app wallet
- In-chat crypto transfers
Over 70,000 community members have already pre-signed up for the beta launch of Ally. The decentralized version of Ally in Beta is expected to be live September 2018 on the TestNet. The MainNet release is expected to be early 2019. To learn more about Ally, please visit: getally.io .
Skrumble Network is backed by Skrumble Technologies Inc and has attracted over 15 world-class venture capital partners. A few noteworthy industry-leading advisors including Anthony Di Iorio (Co-Founder of Ethereum, Jaxx & Decentral), Jeff Pulver (VOIP pioneer, Co-Founder of Vonage), Jinius Tu (CTO of Aion), Redouane Elkamhi, PhD (Associate Professor of Finance at Rotman UofT), and Kevin Hsu (Founder & Managing Partner of Block VC).
The SKM token can currently be traded on Gate.io, LBank, Hotbit, CoinBene, and Fatbtc.
About Skrumble Network
Skrumble Network (SKM) is a new, innovative public blockchain that is uniquely optimized for secure communication-centric connections and transactions, decentralized applications, and offers a communication layer for developers to build into any application. With no middle entity or centralized server host in between to censor, block or manipulate any data, Skrumble Network’s blockchain and decentralized applications aim to be a catalyst for data privacy and help to truly democratize communication on a global scale. For more information, please visit https://skrumble.network/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005093/en/
Contact:
Media:
Skrumble Network
Angel Huang, 778-968-5798
Communications
Specialist
angel.h@skrumble.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom